Clinical Utility of Serum Tumor Markers and Circulating Tumor Cell Assays in the Treatment of Breast Cancer
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2011)
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 12, Issue 4, Pages 403-411Publisher
SPRINGER
Keywords
Categories
Ask authors/readers for more resources
Authors
I am an author on this paper
Reviews
Recommended
Clinical usefulness of circulating tumor markers
Xavier Filella, Maria Rodriguez-Garcia, Esther Fernandez-Galan
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)
Clinical utility of circulating tumor cells: an update
Antoine Vasseur, Nicolas Kiavue, Francois-Clement Bidard, Jean-Yves Pierga, Luc Cabel
MOLECULAR ONCOLOGY (2021)
Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma
Carlos S. Cabalag, Michael Yates, Mariana Benitez Corrales, Paul Yeh, Stephen Q. Wong, Bonnie Z. Zhang, Kenji M. Fujihara, Lynn Chong, Michael W. Hii, Sarah-Jane Dawson, Wayne A. Phillips, Cuong P. Duong, Nicholas J. Clemons
ANNALS OF SURGERY (2022)
Clinical utility of axillary nodal markers in breast cancer
Peter A. Barry, Kathryn Harborough, Victoria Sinnett, Anna Heeney, Edward Robert St John, Tanja Gagliardi, Basrull N. Bhaludin, Kate Downey, Romney Pope, Rachel L. O'Connell, Marios K. Tasoulis, Fiona MacNeill, Jennifer E. Rusby, Gerald Gui, Aikaterini Micha, Samantha Chen, Katherine Dorothy Claudia Krupa
EJSO (2023)
Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility
Caroline Brenner Thomsen, Amanda Dandanell Juul, Anna Cecilie Lefevre, Christina Glismand Truelsen, Edina Dizdarevic, Heidi Ryssel, Ina Mathilde Kjaer, Karen Lycke Wind, Louise Bach Callesen, Louise Faaborg Larsen, Malene Stochkel Frank, Rikke Fredslund Andersen, Karen-Lise Garm Spindler, Anders Jakobsen
CANCER (2022)
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
DIAGNOSTICS (2022)
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
Hitomi Sumiyoshi Okuma, Kan Yonemori, Yuki Kojima, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Susumu Hijioka, Keiko Wakakuwa, Ken Kato, Akihiro Hirakawa, Aya Kuchiba, Takashi Kubo, Hitoshi Ichikawa, Akihiko Yoshida, Yasushi Yatabe, Kenichi Nakamura, Hiroyuki Mano, Noboru Yamamoto, Yasuhiro Fujiwara
FRONTIERS IN ONCOLOGY (2021)
Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
Yang Li, Zhenxing Wang, Rao Fu, Shuang Wang, Tingting Zhang, Xudong Tian, Dawei Yang
FRONTIERS IN ONCOLOGY (2022)
Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer
Heather J. Chalfin, Stephanie A. Glavaris, Michael A. Gorin, Max R. Kates, Megan H. Fong, Liang Dong, Andres Matoso, Trinity J. Bivalacqua, Michael H. Johnson, Kenneth J. Pienta, Noah M. Hahn, David J. McConkey
EUROPEAN UROLOGY ONCOLOGY (2021)
Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility
Jozsef Petrik, Donatella Verbanac, Marija Fabijanec, Andrea Hulina-Tomaskovic, Andrea Ceri, Anita Somborac-Bacura, Roberta Petlevski, Marija Grdic Rajkovic, Lada Rumora, Bozo Kruslin, Mario Stefanovic, Neven Ljubicic, Neven Barsic, Antonija Hanzek, Luka Bockor, Ivana Celap, Alma Demirovic, Karmela Barisic
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Hydrogel-based technologies in liquid biopsy for the detection of circulating clinical markers: challenges and prospects
Young Jun Kim, Junhong Min
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2023)
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
Luc Cabel, Frederique Berger, Paul Cottu, Delphine Loirat, Aurore Rampanou, Etienne Brain, Stacy Cyrille, Hugues Bourgeois, Nicolas Kiavue, Elise Deluche, Sylvain Ladoire, Mario Campone, Jean-Yves Pierga, Francois-Clement Bidard
BRITISH JOURNAL OF CANCER (2021)
Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments
Jie Qiu, Da Qian, Yuancong Jiang, Liwei Meng, Liming Huang
FRONTIERS IN ONCOLOGY (2023)
Circulating tumor DNA: current challenges for clinical utility
Donna K. Dang, Ben H. Park
JOURNAL OF CLINICAL INVESTIGATION (2022)
Clinical application of circulating tumor DNA in breast cancer
Jeffrey Chun Hin Chan, James Chung Hang Chow, Connie Hoi Man Ho, Therese Yue Man Tsui, William C. Cho
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew Wardley, Javier Cortes, Louise Provencher, Kathy Miller, A. Jo Chien, Hope S. Rugo, Joyce Steinberg, Jennifer Sugg, Iulia C. Tudor, Manon Huizing, Robyn Young, Vandana Abramson, Ron Bose, Lowell Hart, Stephen Chan, David Cameron, Gail S. Wright, Marie-Pascale Graas, Patrick Neven, Andrea Rocca, Stefania Russo, Ian E. Krop
BREAST CANCER RESEARCH AND TREATMENT (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma, Vandana G. Abramson, Anne O'Dea, Lauren Nye, Ingrid Mayer, Harsh B. Pathak, Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon Lewis, Jecinta Scott, Jilliann A. De Jong, Yen Y. Wang, Rachel Yoder, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Stephen K. Williamson, Milind A. Phadnis, Gregory A. Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin
CLINICAL CANCER RESEARCH (2021)
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
Chi Yan, Jinming Yang, Nabil Saleh, Sheau-Chiann Chen, Gregory D. Ayers, Vandana G. Abramson, Ingrid A. Mayer, Ann Richmond
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Roisin M. Connolly, Jeffrey P. Leal, Lilja Solnes, Chiung-Yu Huang, Ashley Carpenter, Katy Gaffney, Vandana Abramson, Lisa A. Carey, Minetta C. Liu, Mothaffar Rimawi, Jennifer Specht, Anna Maria Storniolo, Vicente Valero, Christos Vaklavas, Ian E. Krop, Eric P. Winer, Melissa Camp, Robert S. Miller, Antonio C. Wolff, Ashley Cimino-Mathews, Ben H. Park, Richard L. Wahl, Vered Stearns
JOURNAL OF CLINICAL ONCOLOGY (2021)
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
CANCER DISCOVERY (2021)
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente V. Valero, Meredith G. Faggen, Therese M. Mulvey, Ron Bose, Tal Sella, Douglas J. Weckstein, Antonio C. Wolff, Katherine E. Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan S. Zuckerman, Lowell L. Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit L. Cheng, Frederick M. Briccetti, Bryan P. Schneider, A. Merrill Garrett, P. Kelly Marcom, Kathy S. Albain, Patricia A. DeFusco, Nadine M. Tung, Blair M. Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Shoshana Rosenberg, Michelle K. DeMeo, Harold J. Burstein, Eric P. Winer, Ian E. Krop, Ann H. Partridge, Sara M. Tolaney
BREAST CANCER RESEARCH AND TREATMENT (2021)
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER plus Metastatic Breast Cancer (MBC)
Julie A. Means-Powell, Ingrid A. Mayer, Roohi Ismail-Khan, Luis Del Valle, Debra Tonetti, Vandana G. Abramson, Melinda S. Sanders, Richard M. Lush, Claudia Sorrentino, Samarpan Majumder, Lucio Miele
CLINICAL BREAST CANCER (2022)
A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention
Sheila H. Ridner, Mary S. Dietrich, John Boyages, Louise Koelmeyer, Elisabeth Elder, T. Michael Hughes, James French, Nicholas Ngui, Jeremy Hsu, Vandana G. Abramson, Andrew Moore, Chirag Shah
LYMPHATIC RESEARCH AND BIOLOGY (2022)
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop, Sara M. Tolaney
NPJ BREAST CANCER (2022)
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer The MA.32 Randomized Clinical Trial
Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Manuela Rabaglio-Poretti, Som D. Mukherjee, John R. Mackey, Vandana G. Abramson, Conrad Oja, Robert Wesolowski, Alastair M. Thompson, Daniel W. Rea, Paul M. Stos, Lois E. Shepherd, Vuk Stambolic, Wendy R. Parulekar
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Melinda L. Telli, Sara M. Tolaney, Geoffrey Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer
NPJ BREAST CANCER (2022)
Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes
Mary S. Dietrich, Katrina Gaitatzis, Louise Koelmeyer, John Boyages, Vandana G. Abramson, Sarah A. McLaughlin, Nicholas Ngui, Elisabeth Elder, James French, Jeremy Hsu, T. Michael Hughes, Deonni P. Stolldorf, Chirag Shah, Sheila H. Ridner
LYMPHATIC RESEARCH AND BIOLOGY (2023)
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+Breast Cancer
Eric M. Lander, Katherine C. Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G. Abramson
ONCOLOGIST (2023)
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U. Lin, Rashmi K. Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L. Bedard, Virginia Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen Gelmon, Gabriel Hortobagyi, Sara A. Hurvitz, Ian Krop, Sherene Loi, Sibylle Loibl, Volkmar Mueller, Mafalda Oliveira, Elisavet Paplomata, Mark Pegram, Dennis Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric Winer
JAMA ONCOLOGY (2023)